Goldschmidt, H, Lokhorst, HM, Mai, EK, van der Holt, B, Blau, IW, Zweegman, S, Weisel, KC, Vellenga, E, Pfreundschuh, M, Kersten, MJ, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, MS, Broijl, A, Lindemann, HW
, Bos, GMJ, Brossart, P, Kooy, MVM, Ypma, P, Duehrsen, U, Schaafsma, RM, Bertsch, U, Hielscher, T, Jarari, L, Salwender, HJ & Sonneveld, P 2018, '
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial',
Leukemia, vol. 32, no. 2, pp. 383-390.
https://doi.org/10.1038/leu.2017.211